Stockscreener 앱 받기
29.50
1.58%
0.46
시간 외 거래:
30.02
0.52
+1.76%
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Great Lakes Advisors LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's What Happened - MarketBeat
Rice Hall James & Associates LLC Purchases Shares of 618,887 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD) - simplywall.st
UBS raises Acadia Pharmaceuticals stock price target on trial optimism By Investing.com - Investing.com Australia
ACAD Maintained by UBS -- Price Target Raised to $49.00 - GuruFocus
UBS raises Acadia Pharmaceuticals stock price target on trial optimism - Investing.com
GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming - MarketBeat
Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside - TradingView
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
STATE STREET CORP Adds to ACADIA Pharmaceuticals Inc (ACAD) Stak - GuruFocus
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Canaccord reiterates Acadia Pharmaceuticals stock rating on products By Investing.com - Investing.com Canada
Canaccord reiterates Acadia Pharmaceuticals stock rating on products - Investing.com India
Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline - Investing.com India
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data - MarketBeat
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline By Investing.com - Investing.com Nigeria
ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advance - TradingView
Acadia Pharmaceuticals stock hits 52-week high at $29.81 - Investing.com
Acadia Pharmaceuticals stock hits 52-week high at $29.81 By Investing.com - Investing.com Australia
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains Fresh Market Attention - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $41.00 Price Target at Needham & Company LLC - MarketBeat
ACAD Maintains Buy Rating by Needham -- Price Target Raised to $41 - GuruFocus
Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript - AOL.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High: What Now? - Kalkine Media
Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating - Moomoo
Janus Henderson Group PLC Decreases Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week HighWhat's Next? - MarketBeat
Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says - Moomoo
Immunic appoints Elena Ridloff to board of directors - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Raised to $39.00 - GuruFocus
ACADIA Pharmaceuticals Inc. Revenue Breakdown – BIVA:ACAD - TradingView
Sei Investments Co. Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Empowered Funds LLC Purchases Shares of 48,982 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Acadia CFO Mark Schneyer sells $587k in company stock - Investing.com
Acadia CFO Mark Schneyer sells $587k in company stock By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at Wall Street Zen - MarketBeat
Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Mark Schneyer Sells 14,292 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth - Yahoo Finance
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year? - Yahoo Finance
State Street Corporation (ACAD) discloses 5.3% Acadia Pharma stake on 13G - Stock Titan
What is HC Wainwright's Estimate for ACAD FY2026 Earnings? - MarketBeat
Guggenheim Sticks to Its Hold Rating for ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
HC Wainwright Analysts Increase Earnings Estimates for ACAD - MarketBeat
H.C. Wainwright reiterates Acadia Pharmaceuticals stock rating By Investing.com - Investing.com Canada
1.21%
1.07%
자본화:
|
볼륨(24시간):